Selinexor: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), SMC (Scotland) and TLV (Sweden) recommended or restricted selinexor, while CIPM (Spain) and HAS (France) did not recommend it.
PBAC (Australia) has been harder on selinexor than on its own caseload: it refused 4 of 6 decisive submissions here (67%), against a base rate of 24% across everything it has assessed.
The record spans 4.4 years, opening at AWMSG (Wales) on 21 May 2021 and running to 29 Oct 2025.
PBAC (Australia) changed its position: not recommended in 2021, recommended by 2022, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for selinexor, 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 14 of 22 records date from 2023 or later.
Against its own class, selinexor is an outlier: 46% of its decisive outcomes were positive, where molecules sharing ATC class L01X average 75%.
The programme is broad: 10 distinct indication wordings are recorded for selinexor by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
6 of these 22 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess selinexor, on 21 May 2021; DMC (Denmark) did not open a file until 29 Oct 2025 — a wide spread of 4.4 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 5 years in total.
7 of the 11 agencies here assessed selinexor more than once, PBAC (Australia) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for selinexor.
The full ledger for selinexor reads 7 not recommended, 4 recommended, 3 no benefit and 2 restricted, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| TLV (Sweden) | 28 Apr 2025 | Nexpovio ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| NYE METODER (Norway) | 27 Apr 2025 | Kombinasjonsbeh. med deksametason for beh. av multippelt myelom hos voksne pasienter som har fått minst fire tidligere b… | decision recorded | source |
| CIPM (Spain) | 20 Nov 2024 | Indicaciones terapéuticas autorizadas: En combinación con bortezomib y dexametasona para el tratamiento del mieloma múlt… | not financed by the SNS · art. 92 c, d | source |
| SMC (Scotland) | 7 Oct 2024 | In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory … | accepted | source |
| AIFA (Italy) | 3 Aug 2024 | Selinexor in associazione a desametasone per il trattamento del mieloma multiplo in pazienti adulti sottoposti ad almeno… | innovative status not granted · reimbursed class H | source |
17 further decisions for selinexor, across 9 agencies, are not shown here. They include the most recent record on file, 29 Oct 2025 from DMC (Denmark); its outcome is in the subscriber dataset. They link to 12 further source documents.
Related molecules
- panobinostat — divergent outcome (not recommended vs recommended) on a shared indication
- pomalidomide — divergent outcome (not recommended vs recommended) on a shared indication
- elotuzumab — divergent outcome (not recommended vs recommended) on a shared indication
- daratumumab — divergent outcome (not recommended vs recommended) on a shared indication
- teclistamab — divergent outcome (not recommended vs recommended) on a shared indication
- lenalidomide — divergent outcome (not recommended vs recommended) on a shared indication
Coverage: 22 decisions for selinexor from 11 agencies, 2021 to 2025. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.